PT  - JOURNAL ARTICLE
AU  - Chaar, Dima L.
AU  - Li, Zheng
AU  - Shang, Lulu
AU  - Ratliff, Scott M.
AU  - Mosley, Thomas H.
AU  - Kardia, Sharon L.R.
AU  - Zhao, Wei
AU  - Zhou, X.
AU  - Smith, J.A.
TI  - Multi-ancestry transcriptome-wide association studies of cognitive function, white matter hyperintensity, and Alzheimer’s disease
AID  - 10.1101/2024.01.03.24300768
DP  - 2024 Jan 01
TA  - medRxiv
PG  - 2024.01.03.24300768
4099  - http://medrxiv.org/content/early/2024/01/05/2024.01.03.24300768.short
4100  - http://medrxiv.org/content/early/2024/01/05/2024.01.03.24300768.full
AB  - Genetic variants increase the risk of neurocognitive disorders in later life including Vascular Dementia (VaD) and Alzheimer’s disease (AD), but the precise relationships between genetic risk factors and underlying disease etiology are not well understood. Transcriptome-wide association studies (TWAS) can be leveraged to better characterize the genes and biological pathways underlying genetic influences on disease. To date, almost all existing TWAS have been conducted using expression studies from individuals of a single genetic ancestry, primarily European. Using the joint likelihood-based inference framework in Multi-ancEstry TRanscriptOme-wide analysis (METRO), we leveraged gene expression data from European (EA) and African ancestries (AA) to identify genes associated with general cognitive function, white matter hyperintensity (WMH), and AD. Regions were fine-mapped using Fine-mapping Of CaUsal gene Sets (FOCUS). We identified 266, 23, 69, and 2 genes associated with general cognitive function, WMH, AD (using EA GWAS summary statistics), and AD (using AA GWAS), respectively (Bonferroni-corrected alpha=P<2.9−10-6), some of which were previously identified. Enrichment analysis showed that many of the identified genes were in pathways related to innate immunity, vascular dysfunction, and neuroinflammation. Further, downregulation of ICA1L was associated with higher WMH and with AD, indicating its potential contribution to overlapping AD and VaD neuropathology. To our knowledge, our study is the first TWAS of cognitive function and neurocognitive disorders that used expression mapping studies in multiple ancestries. This work may expand the benefits of TWAS studies beyond a single ancestry group and help to identify gene targets for pharmaceutical or preventative treatment for dementia.Author Summary Transcriptome-wide association studies (TWAS) can be used to understand the mechanisms of gene expression that underly disease etiology. However, to date, TWAS methods have mostly been used in a single ancestry group, especially European ancestry (EA), and few TWAS have focused on cognitive function or structural brain measures. We used a newly developed TWAS method called the Multi-ancEstry TRanscriptOme-wide analysis (METRO) to incorproate gene expression data from 801 EA and 1,032 African ancestry (AA) adults to identify genes associated with general cognitive function, structural brain changes called white matter hyperintensities (WMH) that predispose people to vascular dementia, and another form of dementia called Alzheimer’s disease (AD). We found that reduced gene expression of ICA1L was associated with more WMH and with AD, indicating its potential contribution to overlapping AD and vascular dementia neuropathologies. To our knowledge, our study is the first TWAS of cognitive function and neurocognitive disorders using multiple ancestries. This work may expand the benefits of TWAS studies beyond a single ancestry group and help to identify gene targets for pharmaceutical or preventative treatment for dementia.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupport for the Genetic Epidemiology Network of Arteriopathy (GENOA) was provided by the National Heart, Lung and Blood Institute (NHLBI, U01HL054457, RC1HL100185, R01HL087660, R01HL119443, R01HL133221) and the National Institute of Neurological Disorders and Stroke (NINDS, R01NS041558) of the NIH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The University of Michigan Health Sciences and Behavioral Sciences Institutional Review Board gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe phenotype data and APOE genotypes used in the current study are available upon reasonable request to J.A.S. and S.L.R.K., and with a completed data use agreement (DUA). All other genotype data are available from the Database of Genotypes and Phenotypes (dbGaP): phs001401.v2.p1. Methylation and gene expression data are available from the Gene Expression Omnibus (GEO): GSE210256 and GSE138914. Due to IRB restriction, mapping of the sample IDs between genotype data (dbGaP) and methylation data (GEO) cannot be provided publicly, but is available upon written request to J.A.S. and S.L.R.K.